SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

Silver is generating significant community buzz as traders weigh technical breakout levels against shifting macroeconomic indicators like a weakening dollar and cooling labor data. Discussion is heavily split between long-term "stackers" anticipating an explosive supply-demand reset and traders debating whether the recent price action marks a genuine trend reversal or another period of consolidation.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera is currently trending as investors focus on the upcoming Phase 2 clinical data readout for its lead program, ABCL635, which is viewed as a major validation test for the company's antibody discovery platform. The community is actively debating the stock's valuation as a potential biopharmaceutical company, with ongoing discussions centered on its recent strategic partnerships and the potential for a significant rerating following the release of the clinical results.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is capturing significant market attention following its acquisition of three Boeing subsidiariesWisk Aero, SkyGrid, and Insituwhich has brought in an established defense revenue stream and solidified Boeing as a major shareholder. Investors and community members are closely monitoring upcoming earnings and integration progress, while traders debate the stock's potential for a short squeeze against its high short interest.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumble is trending as investors focus on the upcoming earnings report and the company's strategic pivot into AI infrastructure, fueled by its recent Northern Data acquisition, 22,000 GPU capacity, and high short interest that has sparked intense community discussion about a potential short squeeze. Traders are keenly awaiting formal financial guidance and updates on major cloud contracts, which many believe will act as a re-rating catalyst for the stock's valuation.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently the center of active community discussion as investors weigh a strong backlog and recent defense contracts against concerns surrounding potential Neutron launch delays ahead of the upcoming earnings report. The stock is seeing high volatility with traders aggressively debating whether the current momentum will lead to a breakout or if pre-earnings caution will suppress further gains.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as institutional ownership by major firms continues to surge, fueling community speculation about an imminent buyout or positive data readout from the REGAL trial. Investors are actively discussing the upcoming 80th trial event, with many focused on the potential for a market-moving catalyst as the company approaches its next earnings report.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is surging following a record-breaking earnings report that highlighted massive demand for indium phosphide wafers, driven by an expanding AI optical infrastructure cycle and a key long-term supply agreement with Lumentum. The community is fiercely divided, with bulls pointing to the company's critical role in the photonics supply chain and institutional accumulation, while bears argue the stock is overextended and susceptible to risks related to China trade exposure and potential volatility.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is experiencing heightened volatility following a drastic post-earnings sell-off that has triggered a intense debate among investors regarding whether the stock is an oversold opportunity or a broken growth story. While the community is actively tracking institutional accumulation, short interest, and the stock's role in the AI-edge computing sector, sentiment remains sharply divided between those calling for a rebound to previous highs and others bracing for further downside.

Coherent Corp. engages in the development, refinement, manufacturing, and marketing of engineered materials, opto-electronic components and devices, and lasers for use in the industrial, communications, electronics, and instrumentation markets. It operates through the following segments: Networking, Materials, and Lasers. The Networking segment leverages compound semiconductor technology platforms and deep knowledge of end-user applications. The Materials segment markets engineered materials and optoelectronic devices. The Lasers segment serves industrial customers in semiconductor capital equipment, display capital equipment, precision manufacturing, and aerospace and defense, as well as instrumentation customers in life sciences and scientific research. The company was founded by Carl J. Johnson in 1971 and is headquartered in Saxonburg, PA.

Coherent Corp

Coherent Corp is trending as investors weigh potential shifts in AI optical infrastructure demand, with community members actively discussing a reported U.S. proposal to restrict Chinese-made optical transceivers. While the stock has seen high volatility, traders are closely monitoring how supply chain dynamics, upcoming earnings, and strategic partnerships impact the long-term outlook for this essential component of AI hardware.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is rallying following news of a collaborative workshop with Meta to bring WhatsApp and AI services to its satellite network, while investor sentiment is further bolstered by the upcoming launch of three additional BlueBird satellites. Community discussion is heavily focused on the stock's potential for a major re-rating as the company advances its regulatory milestones and commercial partnerships, with many long-term investors dismissing short-term volatility in favor of the stock's massive addressable market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS PR Newswire NASHVILLE, Tenn., Aug. 4, 2026 $100 million Strategic Transaction Closed Special Shareholder Dividend FundedAdvancing Late Stage...

Possible Generic Drug Tariffs and 2 Microcaps

Generic drug tariffs could impact ELTP and CPIX.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS PR Newswire NASHVILLE, Tenn., July 28, 2026 NASHVILLE, Tenn., July 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq...

ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now?

Elite Pharmaceuticals and Cumberland Pharmaceuticals follow different growth paths, but which looks more compelling now? Let's dive in.

CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE

CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE PR Newswire NASHVILLE, Tenn., July 13, 2026 Record Date is July 10, 2026 & Payment Date is July 31,2026Corporate and Insider Share Purchase Initiatives...

Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex

Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex PR Newswire NASHVILLE, Tenn., July 1, 2026 $100 million Transaction Follows Cumberland Shareholder ApprovalStrengthens Cumberland's Focus on Rare Disease...

Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference PR Newswire NASHVILLE, Tenn., June 26, 2026...

RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement

RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement PR Newswire TEL AVIV, Israel and RALEIGH, N.C., June 22, 2026 $6 million upfront with up to approximately $13.4 million of potential aggregate...

RedHill Biopharma Announces Up To $19.4 Million Private Placement

RedHill Biopharma Announces Up To $19.4 Million Private Placement RedHill Biopharma Announces Up To $19.4 Million Private Placement PR Newswire TEL AVIV, Israel & RALEIGH, N.C., June 18, 2026 $6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the...

RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation

RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation PR Newswire RALEIGH, N.C. and...

$CPIX Q2 &#39;26 Earnings Results &amp; Recap

Cumberland Pharmaceuticals reported net revenues from continuing operations of $0.17 million for the three months ended June 30, 2026, compared to $0.38 million for the same period in 2025.

Stocktwits

Cumberland Pharmaceuticals Inc.

 Q2 '26 Earnings Results & Recap

Cumberland Pharmaceuticals reported net revenues from continuing operations of $0.17 million for the three months ended June 30, 2026, compared to $0.38 million for the same period in 2025.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. Its products include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, Sancuso, Boxaban, Vasculan. Dyscorban, and RediTrex. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.

Cumberland Pharma Stock Hits 16-Month High After FDA Approves Liver Drug Regimen: Retail’s Thrilled

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$7.92
Prev Close	$7.80
Open	$8.20
Dividend Yield	0.00%
50-Day Moving Average	$5.18
Beta	0.73
Avg. Volume	119,743.86
PE Ratio	-10.85

52-Week High	$8.23
52-Week Low	$1.43
Market Capitalization	$116.87M
EPS (Annual)	-$0.1909
Price to Book	6.70
Revenue Per Employee	$478,725.07

Feed

News

Sentiment

Earnings

Fundamentals

Info